Novartis Ag (NVSEF) EBITDA (2009 - 2025)

Novartis Ag has disclosed EBITDA across 15 years of filings, most recently posting $4.9 billion for Q2 2025.

• EBITDA for Q2 2025 came in at $4.9 billion, up 21.18% year-over-year; the trailing twelve-month figure through Jun 2025 was $21.7 billion (up 72.62% YoY), and the FY2025 annual result was $17.6 billion, up 21.31% from the prior year.
• EBITDA came in at $4.9 billion for Q2 2025 at Novartis Ag, down from $7.4 billion in the prior quarter.
• In the past five years, EBITDA ranged from a high of $7.4 billion in Q4 2024 to a low of $273.0 million in Q4 2022.
• The 5-year median for EBITDA is $1.3 billion (2021), against an average of $2.3 billion.
• Across the five-year window, EBITDA tumbled 35.96% in 2022 and jumped 1887.18% in 2023, its largest moves.
• Novartis Ag's EBITDA stood at $386.0 million in 2021, then decreased by 29.27% to $273.0 million in 2022, then surged by 1887.18% to $5.4 billion in 2023, then jumped by 36.17% to $7.4 billion in 2024, then slumped by 34.15% to $4.9 billion in 2025.
• The last three EBITDA figures came in at $4.9 billion (Q2 2025), $7.4 billion (Q4 2024), and $4.0 billion (Q2 2024), per Business Quant data.